CA IX - Carbonic anhydrase;
clinical-pathological features and biological outcome;
hypoxia;
immunohistochemistry;
solid human cancers;
stem cells markers;
targeted therapy;
SQUAMOUS-CELL-CARCINOMA;
INVASIVE BREAST-CARCINOMA;
PRIMARY CERVICAL-CANCER;
CA-IX;
LUNG-CANCER;
POOR-PROGNOSIS;
DRUG-RESISTANCE;
MESENCHYMAL TRANSITION;
NECK-CANCER;
BLADDER-CANCER;
D O I:
10.2174/09298673113209990227
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Intrinsic and acquired drug resistance of tumor cells still causes the failure of treatment regimens in advanced human cancers. It may be driven by intrinsic tumor cells features, or may also arise from micro environmental influences. Hypoxia is a microenvironment feature associated with the aggressiveness and metastasizing ability of human solid cancers. Hypoxic cancer cells overexpress Carbonic Anhydrase IX (CA IX). CA IX ensures a favorable tumor intracellular pH, while contributing to stromal acidosis, which facilitates tumor invasion and metastasis. The overexpression of CA IX is considered an epiphenomenon of the presence of hypoxic, aggressive tumor cells. Recently, a relationship between CA IX overexpression and the cancer stem cells (CSCs) population has been hypothesized. CSCs are strictly regulated by tumor hypoxia and drive a major non-mutational mechanism of cancer drug-resistance. We reviewed the current data concerning the role of CA IX overexpression in human malignancies, extending such information to the expression of the stem cells markers CD44 and nestin in solid cancers, to explore their relationship with the biological behavior of tumors. CA IX is heavily expressed in advanced tumors. A positive trend of correlation between CA IX overexpression, tumor stage/grade and poor outcome emerged. Moreover, stromal CA IX expression was associated with adverse events occurrence, maybe signaling the direct action of CA IX in directing the mesenchymal changes that favor tumor invasion; in addition, membranous/cytoplasmic co-overexpression of CA IX and stem cells markers were found in several aggressive tumors. This suggests that CA IX targeting could indirectly deplete CSCs and counteract resistance of solid cancers in the clinical setting.
机构:
Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Genega, Elizabeth M.
Ghebremichael, Musie
论文数: 0引用数: 0
h-index: 0
机构:Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Ghebremichael, Musie
Najarian, Robert
论文数: 0引用数: 0
h-index: 0
机构:
Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Najarian, Robert
Fu, Yineng
论文数: 0引用数: 0
h-index: 0
机构:
Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Fu, Yineng
Wang, Yihong
论文数: 0引用数: 0
h-index: 0
机构:
Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Wang, Yihong
Argani, Pedram
论文数: 0引用数: 0
h-index: 0
机构:
Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Argani, Pedram
Grisanzio, Chiara
论文数: 0引用数: 0
h-index: 0
机构:
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Dana Farber Harvard Canc Ctr, Dept Pathol, Boston, MA USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Grisanzio, Chiara
Signoretti, Sabina
论文数: 0引用数: 0
h-index: 0
机构:
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
Dana Farber Harvard Canc Ctr, Dept Pathol, Boston, MA USA
Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USABrigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA